Lantibiotics as Alternative Therapeutics

524 Pages·2023·9.093 MB·English

by  Sanket Joshi, Rajiv K. Kar, Dibyajit Lahiri, Moupriya Nag

LANTIBIOTICS AS ALTERNATIVE
THERAPEUTICS
This pageintentionallyleftblank
Advances in Biotechnology and Bioengineering
LANTIBIOTICS
AS ALTERNATIVE
THERAPEUTICS
Edited by
S J
ANKET OSHI
Oil&GasResearchCenter,CentralAnalyticalandAppliedResearchUnit,
SultanQaboosUniversity,Muscat,Oman
R K. K
AJIV AR
JyotiandBhupatMehtaSchoolofHealthSciencesandTechnology,
IndianInstituteofTechnologyGuwahati,Assam,India
D L
IBYAJIT AHIRI
DepartmentofBiotechnology,UniversityofEngineering&Management,Kolkata,
WestBengal,India
M N
OUPRIYA AG
DepartmentofBiotechnology,UniversityofEngineering&Management,Kolkata,
WestBengal,India
SeriesEditor
SANKET JOSHI
HEMEN SARMA
AcademicPressisanimprintofElsevier
125LondonWall,LondonEC2Y5AS,UnitedKingdom
525BStreet,Suite1650,SanDiego,CA92101,UnitedStates
50HampshireStreet,5thFloor,Cambridge,MA02139,UnitedStates
TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UnitedKingdom
Copyright©2023ElsevierInc.Allrightsreserved.
Nopartofthispublicationmaybereproducedortransmittedinanyformorbyanymeans,electronicormechanical,
includingphotocopying,recording,oranyinformationstorageandretrievalsystem,withoutpermissioninwritingfromthe
publisher.Detailsonhowtoseekpermission,furtherinformationaboutthePublisher’spermissionspoliciesandour
arrangementswithorganizationssuchastheCopyrightClearanceCenterandtheCopyrightLicensingAgency,canbefound
atourwebsite:www.elsevier.com/permissions.
ThisbookandtheindividualcontributionscontainedinitareprotectedundercopyrightbythePublisher(otherthanasmay
benotedherein).
Notices
Knowledgeandbestpracticeinthisfieldareconstantlychanging.Asnewresearchandexperiencebroadenour
understanding,changesinresearchmethods,professionalpractices,ormedicaltreatmentmaybecomenecessary.
Practitionersandresearchersmustalwaysrelyontheirownexperienceandknowledgeinevaluatingandusingany
information,methods,compounds,orexperimentsdescribedherein.Inusingsuchinformationormethodstheyshouldbe
mindfuloftheirownsafetyandthesafetyofothers,includingpartiesforwhomtheyhaveaprofessionalresponsibility.
Tothefullestextentofthelaw,neitherthePublishernortheauthors,contributors,oreditors,assumeanyliabilityforany
injuryand/ordamagetopersonsorpropertyasamatterofproductsliability,negligenceorotherwise,orfromanyuseor
operationofanymethods,products,instructions,orideascontainedinthematerialherein.
ISBN:978-0-323-99141-4
ForInformationonallAcademicPresspublications
visitourwebsiteathttps://www.elsevier.com/books-and-journals
Publisher:StacyMasucci
AcquisitionsEditor:AndreGWolff
EditorialProjectManager:SamYoung
ProductionProjectManager:FahmidaSultana
CoverDesigner:GregHarris
TypesetbyMPSLimited,Chennai,India
Contents
List of contributors xiii Aminoacidcomposition 29
Preface xix Modeofactionofbacteriocin 32
Otherapplicationsofbacteriocin 32
Importantstepsindevelopmentofbacteriocins 34
1. Quandary of antibiotics and multidrug
Preclinicalstudiesofbacteriocins 34
resistance development: a molecular
Toxicityofbacteriocins 36
genetics-based dilemma 1
Challengesinusingbacteriocinsastherapeutic
DipankarGhosh,ParamjeetSingh,ShubhangiChaudhary, paradigm 37
SampritiSarkarandJosephSaoud Futuredirections 38
Conclusion 39
Introduction 2
References 39
Briefhistoryonassortmentofantibiotics 4
Furtherreading 42
Classificationbasedonoriginofantibiotics 4
Classificationconcerningtheresponsefor
3. Biosynthesis of lantibiotics 43
parasiticcells 5
Classificationbasedonmolecularmechanisms SubhamoyDey,KartikChandraGuchhait,DebaratiJana,
ofantibioticsagainstthepathogen 5 SuparnaMajumder,AnuttamPatra,AmiyaKumarPandaand
ChandradipaGhosh
Generalsynopsisonantibioticresistanceand
multidrugresistancephenomena 10 Introduction 44
Molecularmechanismofantibioticresistanceand
Typesoflantibiotics 45
multidrugresistancephenomena 11
Genearrangement 45
Impactofmicrobialgenetics,microbialphysiology,
Biosynthesisoflantibiotics 47
andstressfactorsonantibioticand/ormultidrug
Precursorpeptidesoflantibiotics 47
resistance 14
TheLanBenzyme 49
Technologiestoaddressantibioticresistanceand/or
TheLanCenzyme 50
multidrugresistance 16 TheLanMenzyme 51
Conclusion 18
TheLanDenzyme 51
Acknowledgment 19
Otherposttranslationalmodifications 52
References 19 Proteasesandtransporters 53
Regulationoflantibioticbiosynthesis 54
2. Antimicrobial peptides and their potent
Autoregulationofnisinproduction 54
mechanism of action 25 Regulationoflacticin3147immunity 55
Additionalregulatoryproteins 55
NayanaPatilandArunaSivaram
Engineeringtechnology 56
Introduction 25 Invivoproteinengineering 56
Bacterialantimicrobialpeptideswithpotent Invitroproteinengineering 56
antibacterialactivity 26 Modesofaction 56
Classificationofbacteriocin 27 Poreformation 57
Secondarystructure 27 LipidIItargetinglantibioticsactivities 57
Lesscommonclassofantimicrobial Sporeoutgrowthinhibition 58
peptides 29 Otherbioactivities 58
v
vi
Contents
Conclusion 58 Actionofantimicrobialpeptideson
References 58 developmentofbiofilmonthesurfaceof
medicalimplants 98
4. Development of recombinant Actionofantimicrobialpeptidesagainst
lantibiotics and their potent uses 65 developmentoforalplaque 99
Useofenzymestopreventbiofilm
VenkataGiridharPoosarla,NagaveniShivshetty,
formation 99
SanjayNagarajanandGobinathRajagopalan
Antibacterialactivityoflantibioticsandbacteriocins
Introduction 66 againsthumanpathogens 99
Thegeneticsoflantibioticbiosynthesis 67 Typesoflantibioticsandotherbacteriocinsproduced
Bioengineeredlanthipeptides 67 fromGPBandGNB 100
Heterologousproductionoflantibioticsby Bacteriocins 101
Lactococcuslactis 69 Differenttypesofbacteriocins 101
HeterologousproductionoflantibioticsbyEscherichia BacteriocinssynthesizedbyGPB 102
coli 71 BacteriocinsproducedbyGNB 102
Heterologousproductionoflantibioticsby Methodofactionoflantibiotics 103
Streptomycesspp 72 Type-A(I)lantibiotics 104
Heterologousproductionoflantibioticsby Type-A(II)lantibiotics 108
yeasts 73 Type-Blantibiotics 109
Theactivityoflantibioticsagainstpathogens 74 Two-componentlantibiotics 109
Othertherapeuticapplicationsoflantibiotics 75 Suppressionofsporegermination 110
Immunemodulation 76 Otherbiologicalroles 110
Neuropathicpainrelief 77 Bioengineeringoflantibioticsandfuture
Anticancertreatment 77 prospects 110
Antiviralcapacity 77 Bioengineering:developingmoreeffective
Foodpreservation 78 lantibiotics 110
Conclusion 78 Futureuse 112
References 79 References 112
5. Mechanism of action of the lantibiotics 6. Lantibiotics, its role in the meat and
on the multidrug-resistant organisms 85 poultry industry 119
AmitChattopadhyay,NitisranjanDasandDeblinaBanerjee SharmisthaSamanta,TanmaySarkar,JoyjitSahaand
RunuChakraborty
Mechanismofdevelopmentofdrugresistance 86
Introduction 86 Introduction 119
Molecularbasisofdrugresistance 90 Lantibiotics 121
Resistancedevelopedbychromosomal Commonlyoccurringproblemsinthepoultryand
mutation 91 meatindustry 126
Horizontalgenetransfer 92 Sourcesofcontamination 127
Recombination 93 Themajorbacterialcontaminantsrelatedtopoultry
Biosynthesisoflantibiotics 93 meat 128
Useoflantibioticsinpreventingbiofilm 97 Bacterialcontaminants 128
Biofilmformation 97 Spoilage-causingbacteria 129
Applicationofantibiofilmagentstoprevent Pathogenicbacteria 130
biofilmformation 98 Bacteriocinscommonlyusedinthemeatandpoultry
Antibiofilmactionofantimicrobialpeptides industry 131
againstmultidrug-resistantbacteriathat Reasonsforusinglantibioticsinthemeatand
producebiofilm 98 poultryindustry 133
vii
Contents
Roleoflantibioticsinthepoultryindustry 134 8. Lantibiotics and its role in dairy product
Roleoflantibioticsinswine 135 preservation 169
Conclusion 137
SaraniSenandArghyaSett
References 138
Introduction 169
7. Application of lantibiotics in canned Advantagesofusinglantibioticsoverchemical
preservation 171
food preservation 147
Whatarelantibiotics? 171
MedhaMaitra,AvijitChakraborty,BananiRayChowdhury, Classificationoflantibioticsusedforthe
AnchitaDasSharma,SutapaRoyMisra,ChaitaliDutta,
preservationofdairyproducts 172
TirthaPratimMandalandSayariBhunia
Lantibioticsproducingorganismsusedinthedairy
Introduction 148 industry 173
Classification 149 Applicationoflantibioticsinthefoodindustry 174
Type-Alantibiotics 149 Structureandfunctionalrolesoflantibioticsindairy
Type-Blantibiotics 150 productpreservation 175
Sometraditionallantibioticsusedinfood Nisin 175
preservation 150 Bioengineeringofnisintoovercomeits
Nisin 150 limitations 179
Lacticin3147 151 Enterocins 182
Lacticin481 152 Lacticin 182
LactococcinB 152 Pediocins 183
Enterocins 152 Repurposingoflantibioticsasanalternatetothe
Subtilin 153 antibiotics 183
PediocinPA-1 153 Suitablehostsystem 184
Modeofaction 154 Noncanonicalaminoacids—extendedgenetic
Type-A(I) 154 alphabets 184
Type-A(II) 155 Immobilizedmetalaffinitychromatography
Biosyntheticpathway 155 immobilization 185
Modulationoflantibiotic Conclusion 186
biosynthesis 155 References 186
Prepeptidesandtheleadersequence 156
Enzymesusedintheposttranslationalsynthesis 9. In vitro studies on a natural lantibiotic:
ofproteins 156 paenibacillin 191
Differentlantibioticsincannedfood
PriyaArumugam,KannappanArunachalam,ShiChunleiand
preservation 157
MubarakAliDavoodbasha
Usageofnisinincannedfood 157
Otherlantibioticsincannedmeat Introduction 192
preservation 159 Peptideantibiotics 193
Otherlantibioticsusedincannedseafood Lantibiotics:structure,function,andmodeof
preservation 160 actions 194
Otherlantibioticsusedincanneddairyproduct Paenibacillin:anext-generationantimicrobial
preservation 161 peptidewithdiversepotentials 196
Hurdletechnologytoenhancefoodsafety 162 BiosynthesisofpaenibacillinbyPaenibacillusspp. 197
Fundamentalapplicationsincanned Antimicrobialefficacyofpaenibacillin 198
food 162 Biotechnologicalapproachesforenhancingthe
Usesofsomelantibioticsashurdles 164 productionofpaenibacillin 198
Conclusion 165 Conclusionandfutureperspectives 199
References 165 References 200
viii
Contents
10. Lantibiotics in antifungal therapy: a 12. Insights at the atomistic resolution of
futuristic approach 205 lantibiotics using multiscale
simulations 241
PrattushaKhan,AnanyaDatta,MedhaBasu,AnweshaChatterjee,
BiswarupBanerjeeandArupKumarMitra
SayantaniGarai,DiproMukherjee,DibyajitLahiri,Ritwik
Banerjee,SanchariDas,ArchismanBhunia,RinaRaniRay,
Introduction 206
SanketJoshiandMoupriyaNag
Lantibiotics:classificationandstructure 206
Lantibiotics:synthesis 207 Introduction 242
Lantibiotics:potentialtargetandaction Lantibioticsagainstbiofilm 242
mechanism 207 Structuralandfunctionalprospectoflantibiotic
Traditionalantifungaltherapeuticagents: nisin 245
limitations 208 Multiscalesimulationsofnisin 246
Lantibioticsasantifungaltherapeuticagent 209 Targetmoleculeandinitialguess 247
Pinensin 209 Moleculardynamicssimulations 247
NisinZ 209 Nisin,epidermin,andgalliderminrevealsimilar
Combinationtherapy 210 buildingmotif 248
Lantibiotics 210 Thesourceofepiderminandgalliderminadvantage
Traditionaldrugs 211 overnisin 249
Steroids 212 Conclusion 250
Conclusion 213 References 250
Authorscontributions 214
Acknowledgment 214 13. Immunogenicity studies on
References 214
lantibiotics 255
NavjyotiChakraborty,AditiJoshi,KhushiAhuja,
ApoorvaVashisht,AdreejaBasu,RamSinghPurtyand
11. In silico studies of interaction of
SayanChatterjee
lantibiotics with virulent proteins 221
Bacteriocins(cid:1)anintroduction 256
NavjyotiChakraborty,ShivaniKumar,SumitKumarVerma,
ClassIlantibiotics 257
RamSinghPurty,AdreejaBasuandSayanChatterjee
Structuralaspects 257
Introduction 221 Unusualaminoacids 257
Typesoflantibiotics 223 Organizationoflantibioticgeneclusters 262
Bioactivityoflantibiotics 226 Thebiosyntheticpathway 263
Databasesoflantibiotics 226 Prepeptidesandroleofleaderthe
Moleculardockingandmoleculardynamics 227 sequence 263
Protein(cid:1)peptidedocking 227 Type-A(I)leaders 264
Typesofprotein(cid:1)peptidedocking Type-A(II)leaders 264
methodology 227 Posttranslationalmodificationpathways
Protein(cid:1)peptidedockingsoftware enzymes 265
programs 230 LanBandLanCenzymeproducts 265
Moleculardocking 230 LanMenzyme 266
Challenges 230 Modificationoftwo-component
Limitationofdocking 230 lantibiotics 266
Virulentproteins 232 EpiD-curatedoxidativedecarboxylation 266
Interactionsoflantibioticswithvirulent Activationandtranslocation 266
proteins 233 Proteolyticcleavagebyspecificleader
Conclusion 234 proteases 266
References 235 LanT:theABCtransporter 267
ix
Contents
Activationandexportofcytolysin 267 Lantibioticandnonlantibiotic
Regulationoflantibioticbiosynthetic monopeptides 302
pathways 267 Lantibioticandnonlantibioticdipeptides 305
Actionmechanismofbacteriocins 268 Regulation,manufacture,andbiosynthesis 305
Pore-forminglantibiotics 269 Mutacinimmunity 311
Nisin-poreformationpathway 269 Conclusion 315
Otherpore-forminglantibiotics 270 References 315
Type-Blantibiotics 270
Thecinnamycinsubtype 270 16. Methods for identification of the
Themersacidinsubtype 271 modes of action of lantibiotics 319
Two-componentbacteriocins 271
SelvarajAlaguLakshmi,KannappanArunachalam,
LactococcinG 271
ShiChunleiandMubarakAliDavoodbasha
Futureprospects 271
References 272 Introduction 320
Furtherreading 275 Modeofactionoflantibiotics 320
Methodsforidentificationofmodeofactionof
14. Case studies: application of lantibiotics lantibioticsinGram-positivebacteria 321
as novel drugs 277 Analysisoflanthipeptide-lipid-II
interaction 321
BanditaDutta,DibyajitLahiri,TanmaySarkar,MoupriyaNag,
Invitrobiosynthesisassay 323
DebasmitaBhattacharyaandRinaRaniRay
Isothermaltitrationcalorimetricassay 324
Discoveryoflantibiotics 278 Lipid-IIcycleinterferingantibioticresponse
Biosynthesisofgeneclustersandring regulatorandsensor(LiaRS)reporterassay 325
structures 280 Moleculardetectionoflipid-IIinteractionwith
Geneorganization 281 lanthipeptide 327
Antibioticresistance 282 Enzyme-linkedimmunosorbentassay 328
Causesofantibioticresistance 283 Thin-layerchromatography 328
Antibioticresistanceleadingtothebacterial Spot-on-lawnassay 328
infections 283 Microscopicanalysis 328
Lantibioticsintherapeutics 286 Bindingassaywithplasmamembranelipid
RoleoflantibioticsagainstGram-positive components 330
bacteria 288 Analysisofporeformation 330
RoleoflantibioticagainstGram-negative Potassiumreleaseexperiment 330
bacteria 290 Poreformationassayusingfluorescencedyes 331
Roleoflantibioticintherapeuticapplications 291 Methodsforidentificationofmodeofactionof
Conclusion 293 lantibioticsinGram-negativebacteria 331
Conflictofinterest 293 Lipopolysaccharidebindingassay 331
Acknowledgment 293 Fluorescentdye-loadedliposomeassay 331
References 293 Conclusion 332
References 332
15. Recent updates in understanding of
molecular genetics of lantibiotics 17. Computational modeling for exploring
production 301 the therapeutic repertoire of
lantibiotics 337
DiproMukherjee,SayantaniGarai,SanchariDas,RinaRaniRay,
VijayUpadhye,DibyajitLahiriandMoupriyaNag MoitrayeeSarkar,MadhuraMondal,DipabarnaBhattacharya,
SouradipBasu,ArupKumarMitraandSayakGanguli
Introduction 301
Classifyinglantibiotics 302 Introduction 338